Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Oct 12, 2021
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Stock Option (Right to buy)
2021-10-07+962,289→ 962,289 totalExercise: $16.00Exp: 2031-10-07→ Common Stock (962,289 underlying)
Footnotes (1)
- [F1]Two-thirds of these stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, and one-third of these stock options vest in full on the fourth anniversary of the October 7, 2021 grant date, all subject to the reporting person's continued employment through the applicable vesting date.